Non-tuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010: Table 1

Russell, Clark D; Claxton, Pauline; Doig, Christine; Seagar, Amie-Louise; Rayner, A.; Laurenson, Ian F.

doi:10.1136/thoraxjnl-2013-204260

Cited by 50 publications

(43 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the sensitivity of this method was lower than the specific culture for acid fast bacilli, this was offset by the fact that samples of routine cultures were more often performed. 39 M. abscessus was the most identified species in our 2 centers as reported also in other studies, 40,41 with the exception of one study, in which M. avium was the most prevalent mycobacterial species. 42 If the M. abscessus isolates from the 4 patients belong to the same clone as shown in the study by Bryant et al, 43 who indicated transmission between patients, will be analyzed in future studies.…”

Section: Discussionsupporting

confidence: 57%

Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade

Raidt¹,

Idelevich²,

Dübbers

et al. 2015

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 57%

Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade

Raidt¹,

Idelevich²,

Dübbers

et al. 2015

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…In Croatia, the overall estimated age-standardized annual incidence of probable NTM-PD was 0.2/100,000 population (2006-2010), with a difference between the coastal (0.4/100,000) and the continental region (0.2/100,000) [40]. In Scotland, the mean incidence rate of NTM episodes was reported to be 2.4/100,000 population, with no clear trend over the years 2000-2010 [41], while increasing NTM isolation incidence rates were observed in another study from the UK, rising from 0.9 to 2.9/100,000 population (1995-2006), and the incidence of NTM-PD rose in the English region of Leeds from 0.8 to 2.0/100,000 population (1995-1999) [9,46]. In Denmark, the NTM-PD incidence increased from 0.6 to 1.5/100,000 population-years from 2003 to 2008 [39].…”

Section: Epidemiology and Emerging Pathogensmentioning

confidence: 99%

“…This is in contrast to the high prevalence of M. abscessus complex on the North American, Asian, and Australian continents, where it is the second most frequent NTM after MAC causing NTM-PD [36,37,38]. In the majority of European countries, M. xenopi (which represents <0.01% of isolated NTM), followed by M. kansasii and M. malmoense , is more frequently encountered in NTM-PD than is M. abscessus in non-cystic fibrosis patients [8,9,39,40,41,42]. …”

Section: Epidemiology and Emerging Pathogensmentioning

confidence: 99%

Pulmonary Disease Caused by Non-Tuberculous Mycobacteria

Wassilew¹,

Hoffmann²,

Andréjak³

et al. 2016

Respiration

127

View full text Add to dashboard Cite

Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are particularly susceptible to NTM pulmonary disease, many affected patients have no apparent risk factors. Host and pathogen factors leading to NTM pulmonary disease are not well understood and preventive therapies are lacking. NTM isolation and pulmonary disease are reported to rise in frequency in Europe as well as in other parts of the world. Differentiation between contamination, infection, and disease remains challenging. Treatment of NTM pulmonary disease is arduous, lengthy, and costly. Correlations between results of in vitro antibiotic susceptibility testing and clinical treatment outcomes are only evident for the Mycobacterium avium complex, M. kansasii, and some rapidly growing mycobacteria. We describe the epidemiology of NTM pulmonary disease as well as emerging NTM pathogens and their geographical distribution in non-cystic fibrosis patients in Europe. We also review recent innovations for the diagnosis of NTM pulmonary disease, summarize treatment recommendations, and identify future research priorities to improve the management of patients affected by NTM pulmonary disease.

show abstract

“…However, the same trend has not been seen in Scotland, where no change was recorded from 2000 to 2010. 2 The incidence of NTM in all sample types almost trebled between 1995 (0.9 per 100,000 population) and 2006 (2.9 per 100,000 population). Between 2007 and 2012, 21,118 individuals had NTM culture-positive isolates; the overall incidence of NTM increased from 5.6 per 100,000 (n=3126, 95% CI 5.4-5.7) to 7.6 per 100,000 (n=4454, 95% CI 7.4-7.9) (p<0.001).…”

mentioning

confidence: 99%